Dataset Information

Circulating basophil count as a prognostic marker of tumor aggressiveness and survival outcomes in colorectal cancer.

ABSTRACT: BACKGROUND:Accumulating evidence demonstrated immune/inflammation-related implications of basophils in affecting tissue microenvironment that surrounded a tumor, and this study aimed to elucidate the clinical value of serum basophil count level. METHODS:Between December 2007 and September 2013, 1029 patients diagnosed with stage I-III CRC in Fudan University Shanghai Cancer Center meeting the essential criteria were identified. The Kaplan-Meier method was used to construct the survival curves. Several Cox proportional hazard models were constructed to assess the prognostic factors. A simple predictor (CB classifier) was generated by combining serum basophil count and serum carcinoembryonic antigen (CEA) level which had long been accepted as the most important and reliable prognostic factor in CRC. RESULTS:The preoperative basophils count

SUBMITTER: Liu Q

PROVIDER: S-EPMC7008108 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Circulating basophil count as a prognostic marker of tumor aggressiveness and survival outcomes in colorectal cancer.

Liu Qi Q Luo Dakui D Cai Sanjun S Li Qingguo Q Li Xinxiang X

Clinical and translational medicine 20200210 1

<h4>Background</h4>Accumulating evidence demonstrated immune/inflammation-related implications of basophils in affecting tissue microenvironment that surrounded a tumor, and this study aimed to elucidate the clinical value of serum basophil count level.<h4>Methods</h4>Between December 2007 and September 2013, 1029 patients diagnosed with stage I-III CRC in Fudan University Shanghai Cancer Center meeting the essential criteria were identified. The Kaplan-Meier method was used to construct the sur ...[more]

PMID: 32037496

Similar Datasets

Project description:BackgroundCurrently, there is no reliable blood-based marker to track tumor recurrence in endometrial cancer (EC) patients. Liquid biopsies, specifically, circulating tumor DNA (ctDNA) analysis emerged as a way to monitor tumor metastasis. The objective of this study was to examine the feasibility of ctDNA in recurrence surveillance and prognostic evaluation of high-risk EC.MethodsTumor tissues from nine high-risk EC patients were collected during primary surgery and tumor DNA was subjected to next generation sequencing to obtain the initial mutation spectrum using a 78 cancer-associated gene panel. Baseline and serial post-operative plasma samples were collected and droplet digital PCR (ddPCR) assays for patient-specific mutations were developed to track the mutations in the ctDNA in serial plasma samples. Log-rank test was used to assess the association between detection of ctDNA before or after surgery and disease-free survival.ResultsSomatic mutations were identified in all of the cases. The most frequent mutated genes were PTEN, FAT4, ARID1A, TP53, ZFHX3, ATM, and FBXW7. For each patient, personalized ddPCR assays were designed for one-to-three high-frequent mutations. DdPCR analysis and tumor panel sequencing had a high level of agreement in the assessment of the mutant allele fractions in baseline tumor tissue DNA. CtDNA was detected in 67% (6 of 9) of baseline plasma samples, which was not predictive of disease-free survival (DFS). CtDNA was detected in serial post-operative plasma samples (ctDNA tracking) of 44% (4 of 9) of the patients, which predicted tumor relapse. The DFS was a median of 9 months (ctDNA detected) versus median DFS undefined (ctDNA not detected), with a hazard ratio of 17.43 (95% CI, 1.616-188.3). The sensitivity of post-operative ctDNA detection in estimating tumor relapse was 100% and specificity was 83.3%, which was superior to CA125 or HE4.ConclusionsPersonalized ctDNA detection was effective and stable for high-risk EC. CtDNA tracking in post-operative plasma is valuable for predicting tumor recurrence.

Dataset Information

Circulating basophil count as a prognostic marker of tumor aggressiveness and survival outcomes in colorectal cancer.

Publications

Circulating basophil count as a prognostic marker of tumor aggressiveness and survival outcomes in colorectal cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets